Recent Advances in PROTAC-Based Antiviral Strategies

Abstract

Numerous mysteries of cell and molecular biology have been resolved through extensive research into intracellular processes, which has also resulted in the development of innovative technologies for the treatment of infectious and non-infectious diseases. Some of the deadliest diseases, accounting for a staggering number of deaths, have been caused by viruses. Conventional antiviral therapies have been unable to achieve a feat in combating viral infections. As a result, the healthcare system has come under tremendous pressure globally. Therefore, there is an urgent need to discover and develop newer therapeutic approaches against viruses. One such innovative approach that has recently garnered attention in the research world and can be exploited for developing antiviral therapeutic strategies is the PROteolysis TArgeting Chimeras (PROTAC) technology, in which heterobifunctional compounds are employed for the selective degradation of target proteins by the intracellular protein degradation machinery. This review covers the most recent advancements in PROTAC technology, its diversity and mode of action, and how it can be applied to open up new possibilities for creating cutting-edge antiviral treatments and vaccines.

Synergizing Proteolysis-Targeting Chimeras and Nanoscale Exosome-Based Delivery Mechanisms for HIV and Antiviral Therapeutics

“…Ultimately, the next 30 years hold the promise of revolutionizing viral disease treatment, transforming the lives of patients worldwide, and paving the way for a future where viral diseases are effectively cured and eradicated. 76,77 ■ ADVANCING ANTIVIRAL THERAPIES:…”

“…Collaborative research efforts, continued investment in technological advancements, and robust clinical trials will accelerate the translation of these innovations into clinical practice. Ultimately, the next 30 years hold the promise of revolutionizing viral disease treatment, transforming the lives of patients worldwide, and paving the way for a future where viral diseases are effectively cured and eradicated. , …”

Small Molecule Drugs Targeting Viral Polymerases

“…While PROTAC technology has been primarily exploited within the anticancer field [195][196][197], its application in the antiviral area is gaining attention [198][199][200][201]. Specifically, PROTAC compounds may be potentially developed against a broad range of viruses by customizing the recruiting ligands to different viral polymerases.…”

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

“…Apoptosis and HBV transactivation may be prevented by the X-protein’s ubiquitin-binding, unstable, and oligomerization regions, according to a previous publication. In 2014, a number of peptide-based PROTAC compounds with an emphasis on the X-protein were developed [ 92 ].…”